IceCure's ProSense® Shows Strong Kidney Cancer Efficacy, Drives Breast Cryoablation Interest at ECIO 2026

summarizeSummary

IceCure Medical reported strong clinical data for its ProSense® cryoablation system in kidney and breast cancer, alongside significant interest and an overbooked master class at a major European oncology conference.

check_boxKey Events

• Strong Kidney Cancer Efficacy

  The ICESECRET trial's final analysis reported an 89.4% recurrence-free rate for kidney tumors ≤3cm treated with ProSense®, with 83.9% of patients remaining recurrence-free at a median follow-up of 4.0 years.

• Positive Breast Cancer Outcomes

  An independent study on early-stage breast cancer showed no residual disease at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes.

• Significant Fibroadenoma Reduction

  Another independent study demonstrated a 92.9% reduction in fibroadenoma volume at 12 months post-treatment using ProSense®.

• High Interest at ECIO 2026

  ProSense® was prominently featured at the European Conference on Interventional Oncology (ECIO 2026), including the first-ever dedicated breast cryoablation master class which was overbooked due to high demand.

auto_awesomeAnalysis

This filing provides crucial positive clinical updates for IceCure Medical, a company that recently disclosed a "going concern" warning. The strong recurrence-free rates for kidney cancer from the ICESECRET trial, coupled with excellent outcomes in breast cancer and fibroadenoma studies, validate the efficacy of their ProSense® technology. The high interest and overbooked master class at ECIO 2026 demonstrate growing commercial momentum and physician adoption, which are vital for the company's long-term viability and ability to secure future financing. This news could significantly boost investor confidence following recent financial concerns, especially as the stock trades near its 52-week low.